121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)

Annals of Oncology ◽

10.1016/j.annonc.2021.10.140 ◽

2021 ◽

Vol 32 ◽

pp. S1430

Author(s):

Y. Yang ◽

J. Pan ◽

H. Wang ◽

S. Qu ◽

N. Chen ◽

...

Keyword(s):

Nasopharyngeal Cancer ◽

Phase Iii ◽

Line Treatment ◽

Double Blind ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70908-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 265 ◽

Author(s):

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

Patient Subgroups ◽

First Line Treatment

Download Full-text

A multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdy442 ◽

2018 ◽

Vol 29 ◽

pp. ix121 ◽

Author(s):

B. Han ◽

K. Li ◽

T. Chu ◽

M. Bi ◽

H. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

118TiP A multicenter, randomized, double-blind, placebo-controlled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progress

Annals of Oncology ◽

10.1016/j.annonc.2021.10.136 ◽

2021 ◽

Vol 32 ◽

pp. S1426-S1427

Author(s):

J. Yang ◽

Y. Pan ◽

F. Ning ◽

L. Lin ◽

X. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Treatment

Download Full-text

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(21)01938-9 ◽

2021 ◽

Vol 16 (4) ◽

pp. S748

Author(s):

C. Zhou ◽

S. Ren ◽

J. Chen ◽

X. Xu ◽

Y. Cheng ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Double Blind ◽

Phase Iii Trial ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs-09-6084 ◽

2009 ◽

Author(s):

N. Robert ◽

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958548.793464802 ◽

2012 ◽

Author(s):

Yiqian Nancy You ◽

Brian Keith Bednarski

Keyword(s):

Colorectal Cancer ◽

Advanced Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

Double Blind ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE ‐3 ( AIO KRK ‐0306)

International Journal of Cancer ◽

10.1002/ijc.33775 ◽

2021 ◽

Author(s):

Lian Liu ◽

Nicole Tonya Erickson ◽

Ingrid Ricard ◽

Ludwig Fischer Weikersthal ◽

Markus M. Lerch ◽

...

Keyword(s):

Colorectal Cancer ◽

Weight Loss ◽

Risk Factor ◽

Independent Risk Factor ◽

Phase Iii ◽

Line Treatment ◽

Phase Iii Trial ◽

Early Weight Loss ◽

First Line Treatment

Download Full-text

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Phase Iii ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group

Annals of Oncology ◽

10.1093/annonc/mdx122 ◽

2017 ◽

Vol 28 (6) ◽

pp. 1288-1293 ◽

Author(s):

J.J.M. Kwakman ◽

L.H.J. Simkens ◽

J.M. van Rooijen ◽

A.J. van de Wouw ◽

A.J. ten Tije ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

Phase Iii Trial ◽

Cancer Group ◽

First Line Treatment

Download Full-text